

# **NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

## **NICE guidelines**

### **Equality and health inequalities assessment (EHIA) template**

#### **Intrapartum care - Fluid balance**

The considerations and potential impact on equality and health inequalities have been considered throughout the guidance development, maintenance and update process according to the principles of the NICE equality policy and those outlined in [Developing NICE guidelines: the manual](#).

This EHIA relates to:

Intrapartum care - Fluid balance

## Appendix [X]: equality and health inequalities assessment (EHIA)

### Intrapartum care – Fluid balance

#### STAGE 1. Surveillance review

No surveillance review was carried out for this update.

#### STAGE 2. Informing the scope

No scoping was carried out for this update.

#### STAGE 3. Finalising the scope

No scoping was carried out for this update.

#### STAGE 4. Development of guideline or topic area for update

*(to be completed by the developer before consultation on the draft guideline or update)*

Intrapartum care guideline (NG235)

Date of completion: 18 February 2025

Focus of guideline or update: Fluid balance

4.1	From the evidence syntheses and the committee's considerations thereof, what were the main equality and health inequalities issues identified? Were any <b>further</b> potential issues identified (in addition to those identified during the scoping process) or any gaps in the evidence for any particular group?
-----	---

No evidence review was conducted for this update. Whilst we are aware of maternity being a key area in CORE20PLUS5, no equalities or health inequalities issues relevant to the specific update were identified by the committee.	
--	--

4.2	How have the committee's considerations of equality and health inequalities issues identified in 2.2, 3.2 and 4.1 been reflected in the guideline or update and any draft recommendations?
-----	--

No equalities or health inequalities issues relevant to the update were identified by the committee.	
--	--

4.3 Could any draft recommendations potentially increase inequalities?
No.

4.4 How has the committee's considerations of equality and health inequalities issues identified in 2.2, 3.2 and 4.1 been reflected in the development of any research recommendations?
No equality and health inequalities issues relevant to the update were identified by the committee.

4.5 Based on the equality and health inequalities issues identified in 2.2, 3.2 and 4.1, do you have representation from relevant stakeholder groups for the guideline or update consultation process, including groups who are known to be affected by these issues? If not, what plans are in place to ensure relevant stakeholders are represented and included?
Peripartum hyponatraemia is not known to affect any particular group of women or pregnant people more than another. As such, no specific groups were requested to consult on this update. Various organisations that can provide comments in relation to equalities and health inequalities issues relevant to the update have been invited to register to become stakeholders.

4.6 What questions will you ask at the stakeholder consultation about the impact of the guideline or update on equality and health inequalities?
None.

Completed by developer \_\_\_\_ Ayisha Ashmore & Maija Kallioinen \_\_\_\_\_

Date \_\_\_\_ 18 February 2025 \_\_\_\_\_

Approved by committee chair \_\_\_\_ Sarah Fishburn \_\_\_\_\_

Date \_\_\_\_ 18 February 2025 \_\_\_\_\_

Approved by NICE quality assurance lead \_\_\_\_ Sara Buckner \_\_\_\_\_

Date \_\_\_\_ 18 February 2025 \_\_\_\_\_

## STAGE 5. Revisions and final guideline or update

***(to be completed by the developer before guidance executive considers the final guideline or update)***

[Guideline(s)/suite title]

Date of completion: [Enter date]

Focus of guideline or update: [XXX]

5.1 How inclusive was the consultation process on the draft guideline in terms of response from groups (identified in box 2.2, 3.2 and 4.1) who may experience inequalities related to the topic?

*[Please provide a summary of relevant stakeholders that were invited to respond to the consultation (and the type of organisation, if known), whether they did respond, and the quality of their response]*

*[Please detail any discussions with the Public Involvement Programme]*

5.2 Have any **further** equality and health inequalities issues beyond those identified at scoping and during development been raised during the consultation on the draft guideline or update, and, if so, how has the committee considered and addressed them?

*[Consider each of the dimensions listed below and indicate whether any additional issues were identified by any stakeholders during consultation, what the issue is, and how the committee has addressed it. Please note that the dimensions often overlap, and the impact of intersectionality and cumulative disadvantage should also be considered and noted.]*

- 1) Protected characteristics outlined in the Equality Act 2010 (age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex, sexual orientation)*
- 2) Socioeconomic deprivation (for example, variation by area deprivation such as Index of Multiple Deprivation, National Statistics Socio-economic Classification, employment status, income)*

- 3) *Geographical area variation (for example, geographical differences in epidemiology or service provision- urban/rural, coastal, north/south)*
- 4) *Inclusion health and vulnerable groups (for example, vulnerable migrants, people experiencing homelessness, people in contact with the criminal justice system, sex workers, Gypsy, Roma and Traveller communities, young people leaving care and victims of trafficking)*

*Please note 'none' as appropriate if no further issues identified]*

5.3 If any recommendations have changed after consultation, how could these changes impact on equality and health inequalities issues?

*[For example outline if there are any recommendations that could make it easier or more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers and facilitators with access for the specific group? Are there any recommendations that address quality and experience for particular groups?]*

5.4 Following the consultation on the draft guideline and response to questions 4.1 and 5.2, have there been any further committee considerations of equality and health inequalities issues across the four dimensions that have been reflected in the final guideline?

*[Outline where in the guideline you have discussed equality and health inequalities issues, specifying the relevant recommendations, rationale and impact sections, and the appropriate sections of the relevant evidence reviews and stakeholder responses. Please summarise any recommendations that have been designed to address these issues. Where no further issues have been identified please note none as appropriate. Please state if the committee has decided they are unable to address these issues and the rationale]*

5.5 Please provide a summary of the key equality and health inequalities issues that should be highlighted in the guidance executive report before sign-off of the final guideline or update

*[Please state whether none, some, or all identified issues were addressed and whether any related research recommendations were made]*

Completed by developer \_\_\_\_\_

Date \_\_\_\_\_

Approved by committee chair \_\_\_\_\_

Date \_\_\_\_\_

Approved by NICE quality assurance lead \_\_\_\_\_

Date \_\_\_\_\_

**STAGE 6. After guidance executive amendments – only if applicable**

***(to be completed by appropriate NICE staff member after guidance executive. This stage should be skipped if GE does not apply)***

[Guideline(s)/suite title]

Date of completion: [Enter date]

Focus of guideline or update: [XXX]

6.1	Outline any amendments related to equality and health inequalities issues suggested by guidance executive and what the outcome was.

Completed by developer \_\_\_\_\_

Date \_\_\_\_\_

Approved by committee chair \_\_\_\_\_

Date \_\_\_\_\_

Approved by NICE quality assurance lead \_\_\_\_\_

Date \_\_\_\_\_